Lilly's tirzepatide slides into FDA fast lane for obesity, turning up heat on Novo Nordisk's Wegovy

Eli Lilly is gaining on rival Novo Nordisk as its dual GIP/GLP-1 med tirzepatide—fresh off an approval pit stop in diabetes—slides into the FDA fast lane. Thursday, Lilly said the FDA flagged its drug for fast-track designation in adults with obesity plus those who are overweight with weight-related health problems.